← All trials
NCT06274853
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 15, 2024
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2024
- First posted
- Feb 23, 2024
- Last posted
- May 30, 2024
- Enrollment
- 70
- Arms / groups
- 11 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Center for Advancing Translational Science (NCATS)Lead sponsor
- LeidosCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.